Archives June 2011

Nichrome India Ltd launched their first indigenously manufactured Spanish technology HFFS machine along with its high speed multilane sachet machine with US technology at the world's biggest packaging exposition Interpack 2011 at Dusseldorf, Germany in May this year. Nichrome TOTPACK HFFS machines will manufacture products such as cosmetics, pharmaceutical powders, juice concentrates, dry fruits, liquid chemicals & gels, capsules & tablets, swabs & tissues, etc. Whereas Nichrome Prodo-Pak High Speed multilane Sachet Machines will promote cosmetics & personal care, pharmaceuticals & nutraceuticals, capsules & tablets, and swans & tissues besides conventional applications like powders and liquid. They bagged their first order for the displayed T110 HFFS machine in the exposition and were approached by USA, Asia, Middle East and Europe and other Western markets. "It was the combination of advanced Spanish technology and credible Indian manufacturing that brought our machine to sell for itself. Nichromes' both technology tie-ups with Spanish more...

Shire,     the     global     specialty biopharmaceutical          company, announced the expansion of its human genetic therapies pipeline through the exclusive licence, in markets outside of North America, for the activin receptor type IIB (ActRIIB) class of molecules being developed by Acceleron Pharma Inc, a private biotechnology company based in Cambridge, Massachusetts. The association will initially investigate ACE-031, Acceleron's lead ActRIIB drug candidate, which is currently in phase 2 of the trial for the treatment of patients with Duchenne Muscular Dystrophy (DMD). DMD is a fatal orphan muscle disease with no current treatment. ACE-031 and other ActRIIB molecules have the potential to be used in other muscular and neuromuscular disorders. Shire and Acceleron will collaborate on   a   worldwide   development programme to advance ACE-031 into a global phase 2/3 clinical programme designed to exhibit disease modification in DMD patients. They would utilize the facility to produce commercial supplies of the product for both parties more...

Olympics     2012     partner, GlaxoSmithKline, has signed a long- term agreement with the World Anti-Doping Agency  (WADA) to create early detection method for medicines with performance- enhancing potential in sport. Under the agreement, GSK scientists would specifically identify substances with a probable or high risk of abuse in sport. These scientists would seek similarity to the pharmacological characteristics of existing performance-enhancing substances and analyses their reaction in the human body. This would include stimulatory effects or improved physical endurance. The historic partnership, which was officially ratified in London on June 23, will see GSK supply WADA with confidential information about medicines in early stage development that will be abused by athletes once they are licenced for appropriate patient use. John Fahey, President, WADA, said, "Our work with the pharmaceutical industry is critical to staying one step ahead of the dopers, who have an ever increasing level of scientific expertise. We are more...

Researchers from Australia have developed a pioneering inhaled spray designed to stop the onset of type 1 diabetes. The diabetes prevention spray vaccine is presently being put through clinical trials and has already produced positive results from mouse- based trials. 52 participants, all aged over 18, are taking part and all have early-stage type 1 diabetes. The nasal vaccine has shown to be successful in human type 1 diabetes, could also be tested with different vaccines for the prevention of other autoimmune diseases such as rheumatoid arthritis and multiple sclerosis Type 1 diabetes is caused when the immune system turns on the beta cells responsible for manufacturing insulin and, as a result, glucose levels in urine and blood surge. These patients are therefore generally prescribed a daily supply of insulin via injection, to bring glucose levels back down. 

"Reduced drug development timelines, smaller batch sizes, increased safety requirements and more stringent validation guidelines are all driving the demand for single-use solutions in drug production," said Ken Frank, Senior Vice President, Pall Corporation & President, Pall's Biopharmaceutical Division. Pall Corporation, a global leader in filtration, separation   and purification, introduces the Pall Allegro™ 200L single-use mixer for high-performance mixing in biopharmaceutical applications from pilot scale to full production. This is designed to provide exceptional mixing performance for a wide range of liquid-liquid and solid-liquid mixing applications,, including compounding, formulation, buffer and media preparation, and pH/conductivity adjustment.  

Thermo Fisher Scientific Inc recently announced a breakthrough workflow to overcome key analytical and informatics challenges in metabolomics. The workflow integrates new application software- Thermo Scientific SIEVE 2.0 differential expression analysis and Mass Frontier 7.0 structural elucidation software with powerful new Thermo Scientific High Resolution Accurate mass (HRAM) instruments: the Q Executive™ high performance bench top quadrupole-Ortemp™ LC-MS/MS and the Orbitrap Elite™ hybrid mass spectrometer. The revolutionary new products accelerate even the most complex metabolomics studies. Thermo Fisher Scientific in North America. "The new capability in SIEVE™ 2.0 software eliminates the most significant bottlenecks in current metabolomics data-processing, enabling scientists to find the most promising putative biomarkers quickly." SIEVE™ software is an automated solution for label-free, semi-quantitative differential expression analysis of proteins, peptides and metabolites. Using this software to pre-filter the high-quality accurate mass data generated by Thermo Scientific mass revolutionary new products accelerate even me most complex metabolomics studies. more...

Greenphire, the industry leading provider of clinical payment communication technology solutions, has recently announced the launch of its Clinical GPS technology, a unique site payment solution that streamlines and automates the clinical payment process for sponsors of all sizes.  Green hire’s Clinical GPS solution utilizes a proprietary validation engine that is capable of analyzing data and triggering payments to a recipient  based on customizable terms negotiated within a contract. By centralizing all payment activity through a technology driven system, Clinical GPS is capable of providing detailed reporting at the site, investigator and vendor level for a single study or across a number of studies. Samuel Whitaker, CEO at Greenphire comments: "Currently we are the only company to offer a centralized reporting and auditing tool for clinical trial payments.

 Bio Rad Laboratories, Inc has recently launched industry leading usability with the new colour touch screens for the C1000 Touch thermal cycler, CFX96 Touch and CFX384 Touch real-time PCR detection turnaround time, flexibility, and adjustable throughput. The CFX96 Touch and CFX384 Touch systems combine the optical technology of the CFX optical reaction modules with the precise thermal control  systems, part of the Bio-Rad 1000-series product line. Researchers can use the enhanced user interface to easily edit, run and save protocols. The design allows users of the CFX96 Touch and the CFX384 Touch to view qPCR amplification traces in real time without an attached computer. The C1000 Touch thermal cycler is ideal for large high-throughput labs, core facilities, and GLP labs that value fast and usability of the C1000 Touch™ chassis. These systems are ideal for labs that value high performance, ease of use and high throughput. Researchers who would like more...

Thermo Fisher Scientific Inc recently announced a breakthrough workflow to overcome key analytical and informatics challenges in metabolomics. The workflow integrates new application software- Thermo Scientific SIEVE 2.0 differential expression analysis and Mass Frontier 7.0 structural elucidation software with powerful new Thermo Scientific High Resolution Accurate mass (HRAM) instruments: the Q Executive™ high performance bench top quadrupole-Ortemp™ LC-MS/MS and the Orbitrap Elite™ hybrid mass spectrometer. The revolutionary new products accelerate even the most complex metabolomics studies Thermo Fisher Scientific in North America. "The new capability in SIEVE™ 2.0 software eliminates the most significant bottlenecks in current metabolomics data-processing, enabling scientists to find the most promising putative biomarkers quickly." SIEVE™ software is an automated solution for label-free, semi-quantitative differential expression analysis of proteins, peptides and metabolites. Using this software to pre-filter the high-quality accurate mass data generated by Thermo Scientific mass revolutionary new products accelerate even me most complex metabolomics studies. more...

A large part of the task of supply chain mangers and logistics companies is to shoulder the responsibility of ensuring patient safety along with doctors. If the drug is not supplied at the right time and in right condition then health of the patients will be affected. The Supply Chain Management (SCM) companies need smooth functioning and certain roadblocks need to be overcome to achieve patient safety and satisfaction. Titash Roy Choudhury The   Indian   pharmaceutical market is expected to reach $20 billion by 2015, growing at a compound annual growth rate (CAGR) of 11.7 per cent during 2005-2015 and establish its presence among the world's leading 10 markets, according to a report by Ernst & Young. "It is one of the fastest growing sectors in India currently," states Prakash Rochlani, Vice President - Business Development, SSEA, DHL Supply Chain. But the most interesting part of this growth is that it more...